Surely you have already heard of the new weight loss injections, which are also referred to as „miracle injections“ in the media. There is something to it. Because in addition to the proven weight loss effect, they reduce the risk of cardiovascular diseases as well as the likelihood of having a heart attack and stroke.

No wonder then that demand far exceeds production capacity. US pharmaceutical giant Eli Lilly is in a leading position here.

Company portrait The US pharmaceutical giant Eli Lilly and Company was founded in 1876 and today, with annual sales of $30 billion, is one of the largest pharmaceutical companies in the world. The US company employs 33,000 employees and produces its drugs in 13 countries. The company’s wide range of products from Indianapolis includes antidepressants, insulin, cancer drugs, erectile dysfunction drugs, and blood pressure reducers.

Growth drivers in recent years have been mainly the diabetes drugs. This is also where the „weight loss injection“ comes from. Originally developed as a diabetes drug, it is celebrating great successes in the treatment of obesity, slowing digestion and producing a feeling of satiety even with small portions of food.

More effective than Novo Nordisk’s weight loss injection? (?) Recent studies on the effects of Eli Lilly and Novo Nordisk’s weight loss injections have recently attracted attention: 42.2% of those treated with Eli Lilly’s Tirzepatid achieved a weight reduction of more than 15% after a year. The main component of Novo Nordisk’s Wegovy, Semaglutid, only 19.3%.

That’s a huge difference, but the results should be taken with caution. The results have not yet been reviewed by experts. Novo Nordisk has also criticized the dosage of its own active ingredient in the study, which was designed for diabetes patients. However, many non-diabetics also participated in the study, which could have distorted the results.

Fight against obesity offers enormous sales potential Basically, both weight loss injections have great potential. Because the market for such products is gigantic. Estimates suggest that currently around 650 million people suffer from obesity worldwide. It is predicted that this number will increase to one billion by 2030.

In such a market, several providers will make a golden nose. Currently, both Eli Lilly and Novo Nordisk are in a top position to secure a large market share, as their weight loss injections already have a license.

But the competition is not sleeping. Numerous pharmaceutical and biotech companies are currently developing similar products. It is quite possible that an even more effective drug is among them. Of course, Eli Lilly will still make billions in sales in this case.